Silvia Costarelli
Overview
Explore the profile of Silvia Costarelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mazzetti P, Spezia P, Capria A, Freer G, Sidoti M, Costarelli S, et al.
J Clin Virol Plus
. 2023 May;
3(2):100149.
PMID: 37128202
No abstract available.
2.
Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, et al.
PLoS One
. 2016 Oct;
11(10):e0160761.
PMID: 27716843
Background: In clinical trials, toxicity leading to tenofovir disoproxil fumarate (TDF) discontinuation is rare (3% by 2 years); however in clinical practice it seems to be higher, particularly when TDF...
3.
Lapadula G, Bernasconi D, Casari S, Maggiolo F, Cauda R, Di Pietro M, et al.
PLoS One
. 2016 Sep;
11(9):e0162320.
PMID: 27632369
Background: Tenofovir (TDF) can cause kidney injury through tubular dysfunction, with or without drop of estimated glomerular filtration rate (eGFR). Whether mild eGFR reductions during treatment should be considered a...
4.
Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, et al.
Int J Epidemiol
. 2015 Oct;
46(2):e12.
PMID: 26445966
No abstract available.
5.
Lapadula G, Costarelli S, Chatenoud L, Castelli F, Astuti N, Di Giambenedetto S, et al.
J Acquir Immune Defic Syndr
. 2015 Feb;
69(3):312-8.
PMID: 25723139
Background: The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis...
6.
Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19571.
PMID: 25394078
Introduction: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous...
7.
Motta D, Brianese N, Foca E, Nasta P, Maggiolo F, Fabbiani M, et al.
AIDS Res Ther
. 2012 Jun;
9(1):18.
PMID: 22703595
Background: The aim of this study was to explore the effects of HCV co-infection on virological effectiveness and on CD4+ T-cell recovery in patients with an early and sustained virological...
8.
Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, et al.
Antivir Ther
. 2008 Aug;
13(4):601-5.
PMID: 18672539
Background: Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation. Methods: The study comprised an analysis of all...
9.
Costarelli S, Torti C, Rodella A, Baldanti F, Paolucci S, Lapadula G, et al.
AIDS Patient Care STDS
. 2008 Jun;
22(6):489-94.
PMID: 18582190
There is a lack of updated estimates of HIV-2 infection in Italy. Moreover, lack of standardized HIV-2 viral load (VL) and drug resistance tests challenges clinical practice. Among 2941 HIV-positive...
10.
Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, et al.
Antivir Ther
. 2008 Jun;
13(3):341-8.
PMID: 18572746
Background: The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations. Methods: HIV-HBV...